Skip to main content

Lynx, on Notice from Nasdaq, Plans to Appeal Delisting

NEW YORK, Dec. 19-Lynx Therapeutics said yesterday that it has received a notice of delisting from Nasdaq, which it plans to appeal.


The company's stock has traded below $1.00 since July 31, meaning that it no longer complies with the Nasdaq listing maintenance standards.


Lynx said in a statement that it will request a hearing from the stock market, and is considering a reverse stock split or transferring its stocks to the Nasdaq SmallCap Market, which has more lenient policies.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.